iBio, Inc. filed a Form 8-K on November 20, 2026, disclosing that it received a written notice from Nasdaq on November 19, 2026, stating its common stock failed to maintain the required minimum closing bid price of $1.00 per share for the preceding 30 consecutive business days.

Key Highlights

  • Deficiency period: iBio's common stock did not meet the $1.00 minimum closing bid price requirement for 30 consecutive business days, from October 8, 2026 through November 18, 2026, according to the filing.
  • No immediate trading impact: The notice has no immediate effect on the listing or trading of the common stock, which continues to trade under the symbol "IBIO" on The Nasdaq Capital Market.
  • Compliance deadline: The company has 180 calendar days, until May 18, 2027, to regain compliance with Nasdaq Listing Rule 5550(a)(2).
  • Compliance path: Compliance may be achieved if the closing bid price reaches at or above $1.00 for a minimum of 10 consecutive business days during the compliance period, though Nasdaq may require a longer period at its discretion.
  • Potential options noted: The company disclosed it "will consider available options to regain compliance," including "effecting a reverse stock split, if necessary."
  • Second compliance period possible: If compliance is not achieved by May 18, 2027, the company may be eligible for an additional 180 calendar days, subject to meeting other Nasdaq listing requirements and notifying Nasdaq in writing.

iBio Discloses Nasdaq Bid Price Notice and 180-Day Compliance Window

According to the Form 8-K filed with the SEC on November 20, 2026, iBio, Inc. (NASDAQ:IBIO) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on November 19, 2026. The notice stated that the company's common stock failed to maintain a minimum closing bid price of $1.00 per share, as required by Nasdaq Listing Rule 5550(a)(2), for the 30 consecutive business days spanning October 8, 2026 through November 18, 2026.

The filing states that the notice carries no immediate effect on the listing or trading status of the common stock, which continues to trade on The Nasdaq Capital Market under the symbol "IBIO." Under Nasdaq Listing Rule 5810(c)(3)(A), iBio has a compliance period of 180 calendar days, expiring May 18, 2027, to bring its common stock back into compliance. The filing explains that compliance can be achieved if the closing bid price equals or exceeds $1.00 for a minimum of 10 consecutive business days at any point during that window, after which Nasdaq would notify the company that the matter is closed. However, the filing notes that Nasdaq "may, in its discretion, require the closing bid price to equal or to exceed the $1.00 Minimum Bid Price Requirement for more than 10 consecutive business days."

If iBio does not regain compliance by May 18, 2027, the filing describes a potential path to a second 180-day compliance period, contingent on meeting continued listing requirements for market value of publicly held shares and all other initial listing standards, with the exception of the minimum bid price, and on providing written notice to Nasdaq of its intention to cure the deficiency. The company disclosed it intends to "actively monitor the bid price of its common stock" and will consider options including a reverse stock split if necessary. The filing was signed by Marc A. Banjak, Chief Legal Counsel.

What Was Disclosed

iBio disclosed receipt of a Nasdaq deficiency notice for failing to maintain the $1.00 minimum closing bid price for 30 consecutive business days, with a compliance deadline of May 18, 2027, and no immediate impact on its listing status.